The U.S. Food and Drug Administration is moving toward a change that could reshape access to compounded versions of popular GLP-1 medications.
On April 30, 2026, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that targets bulk compounding by large outsourcing facilities.
For patients, the practical question is simple. Will cheaper or easier-to-find compounded versions of Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda still be available? The answer, for now, is maybe in limited cases, but the broad bulk supply route could narrow if the proposal is finalized.
What the FDA wants to change
The 503B bulks list may sound like pharmacy paperwork, but it has real-world effects. It identifies bulk drug substances that certain outsourcing facilities can use when they compound medications.
Under FDA rules, outsourcing facilities generally cannot compound a drug from a bulk substance unless the substance is on the 503B list or the drug is on the FDA shortage list at the time it is made. That is why this proposal matters for large-scale supply.
The agency says it did not find a clinical need for outsourcing facilities to make these GLP-1 drugs from bulk ingredients. It is not banning GLP-1 medicines themselves, it is challenging one route used to make compounded versions.
Why GLP-1 drugs matter
GLP-1 is short for glucagon-like peptide-1, a natural hormone signal in the body. In plain English, these medications can help manage blood sugar, slow stomach emptying, and make people feel full sooner.
Some are used for type 2 diabetes, while others are approved for chronic weight management. For many patients, this is not about a quick cosmetic fix, it is part of a long-term medical plan.
The trouble is access. High prices, insurance denials, and earlier shortages pushed many people toward compounded products. When a treatment becomes part of daily life, the pharmacy counter and the monthly bill can matter almost as much as the science.
Access could shrink
Medical News Today interviewed Douglas Ewing of Hackensack University Medical Center, Michael Snyder of Rose Medical Center, Jen Manne-Goehler of Harvard Medical School, and Mir Ali of MemorialCare Surgical Weight Loss Center.
Their shared bottom line was that removing these drugs from the 503B list would likely reduce broad compounded GLP-1 access.
“Most current compounded supply is produced through 503B outsourcing facilities,” Snyder said. Manne-Goehler noted that some compounded GLP-1 drugs may still be available through 503A pharmacies, which compound medications for individual patients with specific prescriptions.
So, the likely outcome is not an overnight disappearance of every compounded GLP-1. It is more like turning down a large faucet. Some patient-specific compounding could remain, but broad access may become harder.
Safety concerns are central
Compounded drugs can serve an important purpose when a patient cannot use an FDA-approved medication. They are not FDA-approved, though, and the agency does not verify their safety, effectiveness, or quality before they reach the market.
That matters with injectable drugs people may measure and use at home. The FDA says compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug, and it warns that poor compounding can lead to quality problems such as contamination or too much or too little active ingredient.
The FDA has reported dosing errors linked to compounded semaglutide, including some events that required hospitalization.
It has also warned about salt forms that differ from the active ingredient in approved drugs, as well as illegal online sales and counterfeit products that may contain the wrong ingredient or harmful substances.
Patients may look elsewhere
If compounded supply falls, some patients may be tempted to buy GLP-1 drugs from sources outside the United States. That is where the situation can get risky.
What should patients do now? Experts urge people currently using compounded GLP-1s to talk with their health care provider before making changes. Stopping suddenly, stretching doses, or switching to an unknown online product can create new problems.
If compounded GLP-1s become harder to get, legitimate options still exist. They may include FDA-approved weight-management medicines, older generic medications, structured medical weight-loss programs, nutrition support, behavioral care, and close clinical monitoring.
Cost remains the hard part
These alternatives may not work exactly like semaglutide or tirzepatide. Some may be less effective for certain patients, and some may not be appropriate because of side effects or medical history.
Patients can also check insurance coverage again, because formularies change. Some drugmakers offer copay cards or assistance programs for eligible people. It is not a perfect fix, but it may be safer than buying a mystery vial.
At the end of the day, the proposal is about the line between access and oversight. Patients want affordable medicines, clinicians want reliable treatment plans, and regulators want drug products made under rules they can defend.
What happens next
The FDA is taking public comments through June 29, 2026, before making a final decision. The agency said it will review submitted comments before deciding whether to finalize the exclusion of semaglutide, tirzepatide, and liraglutide.
The official proposal has been published in the Federal Register.
